NASDAQ:AKTS Aktis Oncology (AKTS) Stock Price, News & Analysis $25.02 -0.98 (-3.77%) Closing price 04:00 PM EasternExtended Trading$25.36 +0.34 (+1.34%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock About Aktis Oncology Stock (NASDAQ:AKTS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aktis Oncology alerts:Sign Up Key Stats Today's Range$24.80▼$26.6250-Day Range$18.27▼$32.3652-Week Range$14.72▼$34.19Volume314,232 shsAverage Volume584,968 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice Target$34.60Consensus RatingModerate Buy Company Overview Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments. The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones. Aktis engages in translational research to move promising molecules from discovery into human testing, and may pursue collaborations or other corporate-development strategies common in the biopharmaceutical sector to accelerate program advancement and broaden development capabilities. As a publicly traded company on the Nasdaq, Aktis Oncology operates within the broader biotech and pharmaceutical ecosystem and reports progress on its programs to investors and other stakeholders. Public disclosures and regulatory filings are the primary sources for up-to-date information on the company’s pipeline, development timelines and corporate plans. I couldn't find sufficiently detailed, independently verifiable public information on specific products, leadership or geographic headquarters to include here without risking inaccuracy. AI Generated. May Contain Errors. Read More Aktis Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreAKTS MarketRank™: Aktis Oncology scored higher than 49% of companies evaluated by MarketBeat, and ranked 105th out of 190 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAktis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAktis Oncology has a consensus price target of $34.60, representing about 38.3% upside from its current price of $25.02.Amount of Analyst CoverageAktis Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Aktis Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aktis Oncology are expected to decrease in the coming year, from ($1.62) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aktis Oncology is -65.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aktis Oncology is -65.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aktis Oncology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.40% of the float of Aktis Oncology has been sold short.Short Interest Ratio / Days to CoverAktis Oncology has a short interest ratio ("days to cover") of 4.99.Change versus previous monthShort interest in Aktis Oncology has recently increased by 13.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAktis Oncology does not currently pay a dividend.Dividend GrowthAktis Oncology does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.73 News SentimentAktis Oncology has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.08 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aktis Oncology this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for AKTS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Aktis Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aktis Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders3.30% of the stock of Aktis Oncology is held by insiders.Percentage Held by Institutions28.84% of the stock of Aktis Oncology is held by institutions.Read more about Aktis Oncology's insider trading history. Receive AKTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aktis Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKTS Stock News HeadlinesAktis Oncology Initiated at Buy on AKY-1189’s Potential to Surpass Current Second-Line Bladder Cancer Chemotherapy BenchmarkJuly 14 at 4:50 PM | tipranks.comTop Brass at Aktis Oncology Cash In With Major Stock DisposalsJuly 10, 2026 | tipranks.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.July 16 at 1:00 AM | Porter & Company (Ad)Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS)June 26, 2026 | theglobeandmail.comAktis is a Strong Buy at Raymond James on therapeutic platformJune 16, 2026 | seekingalpha.comThis Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For TuesdayJune 16, 2026 | benzinga.comAktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowJune 12, 2026 | seekingalpha.comAktis Oncology: Mini-Proteins With A Targeted PunchJune 11, 2026 | seekingalpha.comSee More Headlines AKTS Stock Analysis - Frequently Asked Questions How have AKTS shares performed this year? Aktis Oncology's stock was trading at $21.75 on January 1st, 2026. Since then, AKTS shares have increased by 15.0% and is now trading at $25.02. How were Aktis Oncology's earnings last quarter? Aktis Oncology (NASDAQ:AKTS) announced its quarterly earnings results on Monday, May, 11th. The technology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.01. The technology company earned $3.23 million during the quarter, compared to the consensus estimate of $2.23 million. When did Aktis Oncology IPO? Aktis Oncology (AKTS) raised $300 million in an IPO on Friday, January 9th 2026. The company issued 17,650,000 shares at $16.00-$18.00 per share. When did Aktis Oncology's lock-up period expire? Aktis Oncology's lock-up period expired on Wednesday, July 8th. Aktis Oncology had issued 17,650,000 shares in its IPO on January 9th. The total size of the offering was $317,700,000 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period. How do I buy shares of Aktis Oncology? Shares of AKTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aktis Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aktis Oncology investors own include Enovix (ENVX), Luminar Technologies (LAZR), Ginkgo Bioworks (DNA), NVIDIA (NVDA), Rambus (RMBS), Globant (GLOB) and Compass Pathways (CMPS). Company Calendar Last Earnings5/11/2026Today7/16/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry N/A Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKTS CIK2035832 WebN/A Phone(978) 237-4380FaxN/AEmployees76Year Founded2020Price Target and Rating Average Price Target for Aktis Oncology$34.60 High Price Target$40.00 Low Price Target$31.00 Potential Upside/Downside+38.3%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio19.49 Quick Ratio19.49 Sales & Book Value Annual Sales$6.50 million Price / Sales205.55 Cash FlowN/A Price / Cash FlowN/A Book Value($2.89) per share Price / Book-8.66Miscellaneous Outstanding Shares53,400,000Free Float51,643,000Market Cap$1.34 billion OptionableOptionable BetaN/A Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:AKTS) was last updated on 7/16/2026 by MarketBeat.com Staff. From Our PartnersWhat Saudi Arabia just did to the dollar changes everythingIn June 2024, a 50-year arrangement tying Saudi oil to the U.S. dollar quietly expired. Garrett Goggin, CFA, C...Golden Portfolio | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredAI investors should get ready for a BIG surpriseWall Street insider Jason Bodner - who called Nvidia at $4.50 - says today's most popular AI stocks are about ...Brownstone Research | SponsoredElon just confirmed my predictionElon Musk has officially confirmed a major new financial venture - and over 1 billion dollars is already flowi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aktis Oncology Please log in to your account or sign up in order to add this asset to your watchlist. Share Aktis Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
